JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN

An expert discusses how advances in JAK V617F monitoring have improved the assessment of disease status and guided treatment decisions and how risk assessment tools have transformed the ability to optimize treatment selection in patients with myeloproliferative neoplasms (MPNs).

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.A 68-Year-Old Woman Diagnosed With Primary Myelofibrosis

EP: 2.Molecular Profiling in MPNs: Enhancing Diagnostic Insights

Now Viewing

EP: 3.JAK V617F Monitoring and Risk Assessment Tools: Optimizing Treatment Decisions in MPN

EP: 4.Treatment Insights From RESPONSE: Ruxolitinib Therapy in Hydroxyurea-Resistant/Intolerant Disease

EP: 5.Advances in MPN Management: Insights From MANIFEST-2 and Beyond

EP: 6.Quality of Life in MPNs: Patient-Centered Factors That Shape Treatment Approaches

EP: 7.Academic Perspectives on the Evolving Treatment Landscape in MPNs

Video content above is prompted by the following:

1. Please discuss how advances in JAK V617F monitoring have empowered you to better assess disease status and guide treatment decisions.
2. Please share how risk assessment tools have transformed your ability to optimize treatment selection in patients with MPNs.

Recent Videos

Personalized JAK Inhibitor Selection in Myelofibrosis: Clinical Characteristics, Molecular Profiles, and Treatment Sequencing

Advancing Treatment Paradigms in Myeloproliferative Neoplasms: From Molecular Pathogenesis to Patient-Tailored Therapy

Diagnostic Challenges in Myelofibrosis: Distinguishing Prefibrotic Disease_

The Evolving Landscape of Myelofibrosis: Current Understanding and Clinical Patterns

Insights from COCOON: Prophylactic Dermatologic Management With Amivantamab + Lazertinib in Advanced NSCLC

1L Treatment for Advanced NSCLC

Recap: ELCC 2025 Highlights

Presented at ELCC 2025: Key Takeaways From KRYSTAL-7

ELCC 2025: Insights From the MARIPOSA Study

LAURA Study: NGS Testing in Diagnosis of NSCLC